Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 9, 2013 - Issue 6
Submit an article Journal homepage
1,143
Views
11
CrossRef citations to date
0
Altmetric
Commentary

Peptide intra-tumor injection for cancer immunotherapy

Enhancement of tumor cell antigenicity is a novel and attractive strategy

Daisuke Nobuoka Division of Cancer Immunotherapy; Research Center for Innovative Oncology; National Cancer Center Hospital East; Kashiwa, Japan; Department of Gastroenterological Surgery; Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences; Kita-ku, Okayama, Japan
,
Toshiaki Yoshikawa Division of Cancer Immunotherapy; Research Center for Innovative Oncology; National Cancer Center Hospital East; Kashiwa, Japan
,
Toshiyoshi Fujiwara Department of Gastroenterological Surgery; Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences; Kita-ku, Okayama, Japan
&
Tetsuya Nakatsura Division of Cancer Immunotherapy; Research Center for Innovative Oncology; National Cancer Center Hospital East; Kashiwa, JapanCorrespondence[email protected]
Pages 1234-1236 | Received 31 Jan 2013, Accepted 13 Feb 2013, Published online: 14 Feb 2013

References

  • Chang CC, Campoli M, Ferrone S. HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis?. Curr Opin Immunol 2004; 16:644 - 50; http://dx.doi.org/10.1016/j.coi.2004.07.015; PMID: 15342012
  • Zeh HJ 3rd, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999; 162:989 - 94; PMID: 9916724
  • Oh S, Hodge JW, Ahlers JD, Burke DS, Schlom J, Berzofsky JA. Selective induction of high avidity CTL by altering the balance of signals from APC. J Immunol 2003; 170:2523 - 30; PMID: 12594278
  • Pudney VA, Metheringham RL, Gunn B, Spendlove I, Ramage JM, Durrant LG. DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8+ T cells. Eur J Immunol 2010; 40:899 - 910; http://dx.doi.org/10.1002/eji.200939857; PMID: 20039301
  • Yoshikawa T, Nakatsugawa M, Suzuki S, Shirakawa H, Nobuoka D, Sakemura N, et al. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. Cancer Sci 2011; 102:918 - 25; http://dx.doi.org/10.1111/j.1349-7006.2011.01896.x; PMID: 21281401
  • Nobuoka D, Yoshikawa T, Takahashi M, Iwama T, Horie K, Shimomura M, et al. Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy. Cancer Immunol Immunother 2012; In press http://dx.doi.org/10.1007/s00262-012-1366-6; PMID: 23143746
  • Kaneko K, Ishigami S, Kijima Y, Funasako Y, Hirata M, Okumura H, et al. Clinical implication of HLA class I expression in breast cancer. BMC Cancer 2011; 11:454; http://dx.doi.org/10.1186/1471-2407-11-454; PMID: 22014037
  • Lee HW, Min SK, Ju YS, Sung J, Lim MS, Yang DH, et al. Prognostic significance of HLA class I expressing in gastric carcinoma defined by monoclonal anti-pan HLA class I antibody, EMR8-5. J Gastrointest Surg 2011; 15:1336 - 43; http://dx.doi.org/10.1007/s11605-011-1545-3; PMID: 21512844
  • Torigoe T, Asanuma H, Nakazawa E, Tamura Y, Hirohashi Y, Yamamoto E, et al. Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: unusually high frequency of down-regulation in breast cancer tissues. Pathol Int 2012; 62:303 - 8; http://dx.doi.org/10.1111/j.1440-1827.2012.02789.x; PMID: 22524657

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.